Articlenpj antimicrobials and resistance2025
Tazobactam selects for multidrug resistance.
Article in npj antimicrobials and resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exploring the Effectiveness of Imipenem/Relebactam in Patients with Antimicrobial-Resistant Hospital-Acquired Infections: Findings from Systematic Literature Reviews.Antibiotics (Basel, Switzerland) · 2026Review
- Phenotypic Characterization ofAntibiotics (Basel, Switzerland) · 2025Article
- High Frequency of Detection of NDM-Producing Enterobacterales Among Companion Animals Hospitalized in an Italian Veterinary Teaching Hospital.Transboundary and emerging diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Piperacillin-Tazobactam is a β-lactam/β-lactamase inhibitor combination that is amongst the most prescribed antimicrobials in hospital medicine. Piperacillin is inactivated by many common beta-lactamases, but tazobactam inhibits these, allowing successful treatment. The effect of piperacillin on Gram-negative bacteria has been widely studied, but less attention has been paid to the effects of tazobactam. We used a massive transposon mutagenesis approach (TraDIS-Xpress) to identify genes in Escherichia coli that affect survival when exposed to piperacillin and tazobactam, separately and together. We found significant differences between the two drugs: a striking finding was that multiple efflux pump families and regulators were essential for survival in the presence of tazobactam, but only one efflux system was beneficial for piperacillin. Exposure of Escherichia coli and Klebsiella pneumoniae to piperacillin and/or tazobactam selected for mutants with reduced susceptibility, and tazobactam selected for efflux and cell envelope mutants associated with multidrug resistance. We identified other pathways involved in tazobactam susceptibility, including the shikimate kinase AroK. Genes involved in DNA replication and repair reduced E. coli susceptibility to a combination of piperacillin and tazobactam but were not identified after exposure to either drug alone. Tazobactam can select for mutants with increased efflux activity, and the development of future β-lactamase inhibitors should consider potential selective impacts of both inhibitor and antibiotic.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.